Pre-Menstrual Syndrome Treatment Market By Drug (Analgesics (Pain Killers), Oral Contraceptive Pills (OCPs), Gonadotropin-Releasing Hormone (GnRH), Antidepressants, Ovarian Suppressors, Diuretics, Benzodiazepines) - Growth, Future Prospects And Competitive Analysis, 2016 - 2024

Pre-menstrual syndrome (PMS) is a medical condition in women that occurs during childbearing age. It is estimated that more than one in three women suffer from PMS; and one in every twenty women demonstrate life disturbing symptoms. Pre-menstrual dysphoric disorder (PMDD) is a further severe form of PMS and demonstrates more severe symptoms of PMS, often interfering with social activities, work and emotional balance. PMDD occurs in 3% to 5% of menstruating women. Though the exact cause of PMS is unknown, it is reported that fluctuating levels of hormones (estrogen and progesterone) are related to PMS symptoms. The treatment regimen of PMS is temporary i.e. administered only for symptom management before the onset of menstrual cycle. Education, nutrition, exercise and medication together form the complete layout of PMS treatment module.

The report titled “Pre-menstrual Syndrome Treatment Market - Growth, Future Prospects and Competitive Analysis, 2016–2024” offers strategic insights into the overall pre-menstrual syndrome treatment market along with the market size and estimates for the duration 2014 to 2024. The said research study covers in-depth analysis of multiple market segments based on type of drugs and different geographies. The drug types studied for analyzing the overall global pre-menstrual syndrome treatment market are majorly segmented into analgesics (pain killers), oral contraceptive pills (OCPs), gonadotropin-releasing hormone (GnRH), antidepressants, ovarian suppressors, diuretics and benzodiazepines.

Geographically, the global pre-menstrual syndrome treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2014-2024. Market growth rates for the forecast period 2016-2024 are also included in this report, considering 2015 as the base year

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global pre-menstrual syndrome treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global pre-menstrual syndrome treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global pre-menstrual syndrome treatment market. In-depth competitive environment analysis and historical (2014) market size data are also provided in the report.

Pre-Menstrual Syndrome Treatment Market

Based on the type of drugs, the global pre-menstrual syndrome treatment market is segmented as follows:

  • Analgesics (pain killers)
  • Oral Contraceptive Pills (OCPs)
  • Gonadotropin-releasing Hormone (GnRH)
  • Antidepressants
  • Ovarian Suppressors
  • Diuretics
  • Benzodiazepines

Common painkillers available for treating PMS are NSAIDS and paracetamol. This segment is majorly dominated by over-the-counter drugs that are cheap and easily available in the market. For depression and anxiety, particularly in patients with PMDD, drugs such as SSRIs (commonly fluoxetine and sertraline) are commonly prescribed. GnRH i.e. synthetic hormones are prescribed to initiate temporary menopause in patients with severe PMS. It is observed that the demand for hormone-based PMS treatments is on a perpetual rise and will continue through the forecast period.

Pre-Menstrual Syndrome Treatment Market

For the purpose of this study, the global pre-menstrual syndrome treatment market is geographically categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Pre-Menstrual Syndrome Treatment Market

At present, North America and Europe dominate the premenstrual syndrome treatment market due to increase in prevalence of premenstrual syndrome and higher awareness about syndrome and prevailing treatment options. Asia Pacific and Middle East and Africa together present lucrative opportunities to manufacturers offering PMS treatment drugs. Large pool of females in childbearing age, growing literacy rate and working population significantly contribute to growing opportunities in the region. Growing number of government initiatives and campaigns focusing on women and maternity health are further driving the market growth.

Choose License Type
Published Date:  Mar 2017
Category:  Pharmaceuticals
Report ID:   58371
Report Format:   PDF
Pages:   120
Rating:    4.4 (60)
Connect With Us
24/7 Research Support